NO ONE SHOULD DIE OF CANCER
Tocagen believes the immune system can be safely activated to fight the patient’s cancer. Driven by this vision, we are developing first-in-class, broadly applicable, product candidates designed to activate a patient’s immune system against their own cancer from within.
Tocagen is advancing a pipeline of novel cancer-selective gene therapies, including Toca 511 & Toca FC, in a global Phase 3 clinical trial for patients with brain cancer.
Our Science
Tocagen is advancing a broadly applicable, cancer-selective gene therapy platform that is designed to deliver therapeutic genes into the DNA of cancer cells and activate a patient’s immune system against their own cancer from within.
Patients
Tocagen is committed to fighting cancer. We have multiple clinical trials ongoing with our lead cancer-selective gene therapy product candidate, Toca 511 & Toca FC.
Investors
Tocagen offers investors several resources to learn more about the company, including press releases, presentations and scientific publications.
